MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
公司代碼MXCT
公司名稱MaxCyte Inc
上市日期Mar 29, 2016
CEOMasoud (Maher)
員工數量114
證券類型Ordinary Share
年結日Mar 29
公司地址9713 Key West Avenue,
城市ROCKVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20850
電話13015175556
網址https://www.maxcyte.com/
公司代碼MXCT
上市日期Mar 29, 2016
CEOMasoud (Maher)